Purpose To critically appraise therapeutic innovations tested in randomized controlled trials (RCTs) in multiple myeloma from Design We performed a comprehensive search to identify published RCTs in multiple myeloma. Quality dimensions of the design, conduct, analysis and reporting of each trial were assessed.
Introduction
Randomized controlled trials (RCT) have become the gold standard for minimizing bias in evaluating new treatment strategies. Thousands of controlled trials are published every year in over 16,000 biomedical journals [1] . Although healthcare professionals rely on these reports to make informed treatment decisions, interpretation of RCT results can be problematic if the quality of the study report is lacking. Institutional review boards were established to protect patients from poorly designed trials [2] and the peer-review process works to improve the reporting of randomized controlled trials [3] , yet RCT study quality has improved little with time [1] .
In recent years mounting empirical evidence has pointed to methodological and journalistic flaws associated with inflated results or higher probabilities of an innovative treatment's success Schulz et al demonstrated that inadequate concealment of treatment allocation was associated with exaggerated estimates of treatment effect by up to 41% [4] . Colditz and colleagues have demonstrated that non-randomized and pseudo-randomlzed studies are more likely to find an innovative treatment to be successful than an appropriately randomized study [5] . Selection bias and lack of blinding have long been regarded as study defects, and yet they continue to be common in randomized controlled trials [1] . Consequently, physicians often rely on the reputation of the journal or the author to assess the validity of a study. However, the peer review process does not guarantee validity [6] and Oxman and Guyatt found an inverse relationship between an authors perceived expertise and the methodologic quality of their review [7] . RCTs sponsored by the pharmaceutical industry have also recently been shown to be biased towards positive outcomes [8] [9] [10] . With the increased demand for randomized controlled trials and the pressure to produce them, researchers and consumers of research alike must be aware of the quality of the existing literature as well as those quality aspects related to possible bias.
Multiple myeloma is a common hematologic disorder representing about 10% of all hematologic malignancies. It is responsible for 19% of all deaths due to hematologic malignancies [11] . Almost all major therapeutic advances for treatment of this disease have occurred as a result of RCTs However, the overall success of these innovative efforts in randomized trials has not been formally evaluated until now.
To address the concerns described above, we 1) formally described the nature and content of the medical literature in a single disease, multiple myeloma, 2) assessed all published RCTs in multiple myeloma for those elements of study design and reporting associated with bias, and 3) evaluated the relative benefits and harms to patients enrolled in randomized controlled trials of innovative treatments in multiple myeloma
Methods
We identified published randomized controlled trials in multiple myeloma from the period 1966 (the first year in which the MEDLINE electronic database became available) to 1998 using the Cochrane search strategy [12, 13] We initially identified 458 papers and excluded 344 articles from analysis due to lack of randomization (167 studies), study duplication (5 studies), and analysis of subgroups only (172 studies) Mela-analyses, systematic reviews, and non-original research were also excluded No attempt was made to identify unpublished trials One hundred fourteen articles reporting one hundred thirty-six RCTs met the inclusion criteria While no strategy for the identification of RCTs is ideal [12] , this represents the most complete database of randomized controlled trials reported for multiple myeloma to date [13] Nevertheless, it must be understood that our report pertains only to available published evidence and not to all potential existing evidence Randomized trials may suffer from a number of methodologic inadequacies that may negatively impact the validity of the outcomes reported In most instances the only way to evaluate study validity is through the article's reporting [14, 15] We assessed the most important criteria related to patient and disease outcomes and study design (Table I ) These criteria included those quality dimensions that are either empirically linked to bias or are generally considered to be the most important elements of RCT quality [15] I) appropriate and concealed randomization [4] , 2) appropriate double-blinding [4] , 3) detailed description of withdrawals and drop outs [16, 17] , 4) intention to treat statistical analysis [18, 19] , 5) criteria for assessing statistical significance (a error) specified in advance, 6) calculation of study power or required sample size [20] , and 7) data or lack of data on adverse events reported [21] We previously reported analysis according to funding and Jadad quality score as a global measure of the quality of randomized trials [10] In this paper we focus on analysis of the most important dimensions for the assessment of the quality of randomized trials
To assess the influence of journal of dissemination and study institution on a randomized controlled trial's quality and reported conclusion we also abstracted data on journal impact factor and the country where the study was performed The impact factor of a journal, a statistic produced annually in the Journal Citation Report of the Institute for Scientific Information, is a ratio obtained by dividing citations received in one year by papers published in the two previous years [22, 23] Studies were evaluated by a single rater (ML) The first author performed an independent validation of a random subset of 40 of these reports (30%) with consistent results
To provide a general picture of the success of innovative therapies in randomized trials we provided the unweighted average of the survival difference and treatment-related mortality difference in myeloma trials We also calculated the average survival and mortality difference n Dune and Salmon described the staging system in 1975, only trials published after this year are included weighted by trial enrollment, but it was within 1% of the unweighted mean (results not shown) We supplemented this calculation with an empirical Bayes analysis, which transformed the distribution to minimize the effect of outliers on the mean (trials are weighted by their distance from the natural mean and then averaged) This calculation was slightly more conservative for survival differences but equivalent to the unweighted mean for mortality differences Bayes analysis was additionally used to predict the probability of attaining a specific survival benefit in a future trial based on the prior distribution of outcomes in myeloma trials [24] The unit of analysis was the individual RCT However, since some papers described more than one RCT we also repeated the analysis using only the most important RCT from each article as the unit of analysis Since the results of the analysis did not significantly differ using either the article or the RCT as the unit of analysis, only the results based on the RCT will be reported The authors of the original reports usually made reference to which treatment was being used as the comparator (standard treatment) and which treatment was being evaluated (innovative treatment), hence we encountered no significant difficulty categorizing the treatments as either innovative or standard We used summary statistics to report the percentage of trials that incorporated any given quality item Some innovative treatments crossed over to the standard treatment category over time In 12 cases an innovative treatment became standard, and in 8 cases a standard treatment was used as an innovative therapy (as when two accepted standard treatments are compared to one another) The results of our analysis were not altered by the inclusion or exclusion of these cross over treatments and they were not excluded in our final analysis Data on survival differences between standard and innovative treatments followed a normal distribution as assessed by the Wilks Shapiro test Student's Mest was used to compare the difference in the survival means between standard and innovative therapies To test for quality differences over time, reports were grouped by decade and quality dimensions were compared with a chi-square analysis Spearman's rank correlation was also employed to test the relationship between quality dimensions, impact factor and time All statistical analyses were done using the statistical package SYSTAT [25] Results
Type and content of randomized controlled trial reports
During the period from 1966-1998, 80 different types of treatments for multiple myeloma have been studied in randomized controlled trials. Figure 1 summarizes the type and content of randomized controlled trials performed in multiple myeloma since 1966. Induction treatment of multiple myeloma was studied in 80 (58%) trials, consolidation in 6 (4%), salvage treatment in 3 (2%), maintenance in 24 (18%), supportive therapy in 20 (15%) and stem-cell mobilization (category 'others' in Figure 1 ) in 3 (2%) of the reports. Conventional dose chemotherapy (usually combination chemotherapy vs. melphalan and prednisone) was studied in 105 (77%) trials, high-dose in 4 (3%), biological response modifiers alone or in combination with chemotherapy in 10 (8%), and various other forms of treatments (e.g., lmmunoglobulins for prevention of infection, bisphosphonates in prevention of skeletal-related morbidity, etc.) were evaluated in 17 (13%) trials Reports on randomized trials in myeloma came from 20 countries; 48 (35%) of the studies were conducted in the US The outcome of interest was survival in 111 (82%) studies. Observed differences in survival vary over time and can be significantly influenced by the length of follow-up [14] Only 15 (14%) studies described outcome beyond five-year survival and just one study reported data beyond 10-year survival The vast majority of studies reported short-term outcomes. Next to survival, progression-free/disease-free survival is considered the most important patient related outcome [26] . However, progression-free/disease-free survival was not reported in 67 (60%) of these papers. Non-survival outcomes reported in the remaining 25 studies included the number of infections, stem-cell collections, skeletal-related events, etc. Data on overall survival and progression-free/disease-free survival are summarized in Table 1 Category of treatment The stage and seventy of a disease can have a major impact on the result of a therapeutic intervention. The stage of multiple myeloma patients was reported in only 68% (66 of 98) of the studies after this staging system was first described (Table 1 ) [27] . Data on complete response and partial response were described in 45% (50 of 111) of the studies that included survival outcomes as their main endpoint In addition, criteria for the definition of complete and partial responses were nonuniform making it difficult to compare studies among themselves At least, three different definitions of complete response and response rate were used.
Abstraction and analysis of data on adverse events presented even greater difficulties. It was not possible to tell whether lack of reported adverse events meant that the event did not occur or that data on the event was not collected or reported. Most likely these events had been collected but not reported. For all 136 RCTs in multiple myeloma, data on non-fatal adverse events were reported in the innovative treatment arm in 91 (67%) trials and in the control arm in 81 (60%) trials (Table 1) . Treatmentrelated mortality was reported in 33 (24%) studies for innovative therapies and in 31 (23%) studies for control therapies. Although these figures likely represent underreporting, the lack of reporting on adverse events reflects a severe limitation in the available body of evidence.
The outcomes of innovative treatment testing
The therapeutic progress made in multiple myeloma through randomized controlled trials has been small but significant since 1966. Innovative treatments tested in myeloma over 30 years were found to result in a 5% (95% confidence interval-1 5%-8.6%, P = 0.003) average improvement in five year survival over standard treatment comparators Empirical Bayes analysis resulted in a more conservative average of 3 6%. However, it is Figure 2 Outcomes of trials in myeloma according to type (survival vs non-survival) and detected statistical significance Note that survival outcomes were studied more often than non-survival ones (82% vs 18%) However, statistically significant outcomes were found more often in non-survival studies (64% vs 28%) Supportive care studies were much more likely to result in a significant positive outcome than efforts aimed at disease control important to note that our analysis cannot identify specific interventions responsible for this average improvement over time. The 5% survival difference expressed in terms of the evidence-based therapeutic summary measure 'number needed to treat' [28, 29] would suggest that for every 20 patients enrolled into the innovative treatment arm, one more would survive to five years. To detect a survival difference of this magnitude with 95% confidence at the individual trial level, we would need to enroll 2188 for five years. The largest myeloma trial enrolled 630 patients.
The most common innovative treatment studied was interferon alone in 17 (13%) studies or in combination with chemotherapy in 14 (10%) studies. The most common standard treatment comparator was melphalan and prednisone (MP) which was studied in 46 (34%) trials Figure 2 shows the proportion of statistically significant positive results for innovative and standard treatments, respectively. The majority of studies reported statistically non-significant results. However, because a power calculation was stated in only 9% of the trials (Table 1) , and the actual power of most of the trials was low (Figure 3) , it is likely that many of the non-significant results were false-negative instead of true negative results Only 23% of the studies reported a significant effect on survival. Statistically significant positive studies were more often reported in supportive, non-survival types of treatment (Figure 2) We also investigated whether patients were more likely to be put at risk as a result of innovation testing with randomized controlled trials. There was a slight mean increase of 0.35% in treatment-related deaths. This statistic means that, on average, for every 286 (100/ 0 35) patients enrolled into the treatment arm of an RCT, one additional patient will suffer a lethal complication over those receiving standard therapy. New treatments were also found to yield 3 8% more non-lethal grade 3-4 side effects, so that for every 25 (100/3 8) patients on the innovative arm, one more will experience a severe side effect than those on the standard treatment arm How- Figure 3 Size of randomized trials in myeloma The two vertical lines denote details regarding the power analysis to detect the postulated difference in survival at five years Note that the vast majority of trials were not powered to detect the difference in survival that was assumed ever, the level of reporting on adverse events was low. These statistics were based only on those RCTs reporting adverse events and thus may not be truly representative.
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Evaluation of the quality of randomized controlled trials
Among quality aspects linked to bias, incomplete description of withdrawals and inadequate double-blinding has been empirically linked to inflated outcomes [4] . Although double-blinding is difficult to perform in chemotherapy-related studies, it can and should be used in treatments with limited or no obvious side-effects. No double-blinded studies were conducted in therapeutic regimens. A double blinded design, however, was used in 95% (22 of 23) of the trials that tested supportive therapies. Appropriate description of double-blinding was reported in 86% (19 of 22) of these studies. Allocation concealment was reported in only 30% (35 of 114) of all studies. A description of withdrawals and dropouts was provided in 78% (106 of 136) of the studies (Table 1) .
Lack of statistical power represents another major limitation in the medical literature on multiple myeloma. Only 12 (9%) studies reported a pre-study calculation of power (P error) ( Table 1 ). Figure 3 displays the relative power and distribution of sample sizes employed in RCTs of multiple myeloma Almost all the RCTs (123 of 136) were ranked as low power evidence according to the Oxford grading system for medical evidence [30] . Forty trials (30%) had sufficient power (0.2 p error) to detect a 20% difference in survival at five years. Only 1 trial (0 75%) was sufficiently powered to detect a 10% survival difference at five years. Based on the prior distribution of myeloma trials the Bayesian probability that a future trial would have a 10% survival difference is about 30% and the chances that a trial would have a 20% survival difference is less than 5% Although we hope for large improvements in survival, the lack of power to detect moderate clinical improvements may imply that either investigators were not aware of the importance of power calculations in planning their study, that there were significant barriers to patient accrual, or that they greatly overestimated the size of the treatment effect.
A critical principal of RCT analysis often overlooked is that final outcomes should be based on an 'intention to treat' (ITT) analysis [19, 31] . It is now widely accepted that all patients should be analyzed with their randomization group whether they received the treatment or not to minimize bias and provide the most generalizable results [18] . However, only 7% (10 of 136) of the studies were analyzed on an ITT basis (Table 1 ) Even the studies analyzed by ITT provided very few details for assessing its methodological adequacy [19] .
When quality dimensions were compared to country of origin we found no difference between US and international studies with respect to the appropriateness of randomization and allocation concealment. US trials, however, more often included description of withdrawals and dropouts in their reports than studies conducted overseas (87% vs. 73%; P = 0.08). Pre-planned statistical significance (a error; US = 4% vs. non-US = 23%, P -0.007) and power calculation (a error; US = 0% vs non-US-13%; P = 0.008) were better reported in internationally conducted studies. US trials were also less likely to be done according to ITTanalysis (0% vs. 8 5%, F = 0013)
The impact factor of a journal has sometimes been used as a measure of a journals prestige [23] . The number of low impact factor journals has also exploded in recent years to keep pace with the demand to publish an ever burgeoning body of scientific evidence Before 1976 all myeloma trials were published in journals that now have impact factors >4, whereas two thirds of clinical trials after 1996 were published in journals with a current impact factor < 4 We found no strong correlation between any of the quality dimensions and journal impact factor, however, there was a trend towards appropriate randomization (40% vs. 21%, P = 0.08), randomization concealment (26% vs. 13%, P -0.07), and double blinding (15% vs. 4%, P = 0.009) in journals with an impact factor > 4 It does not appear likely that any single quality dimension influences preferential publication in often cited journals. When clinical trials were analyzed over time, there were many more pharmaceutically sponsored trials in the 1990s compared to previous decades (35% vs 6%, P < 0.001). Quality dimensions such as precalculation of a error (16% vs. 4%, P = 0 009) and intention-to-treat analysis (8% vs. 0%, P -0.002) were also much more common in the last decade compared to previous decades. However, the other quality dimensions have remained relatively unchanged over the years
Discussion
From 1966 to 1998, 114 papers describing 136 randomized controlled trials have evaluated over 80 different treatments in multiple myeloma Although overall survival gains of 5% at 5 years may be considered modest, these treatments were 14 (5%/0 35%) times more likely to report findings that would help or prolong survival than to harm. Statistics produced by the American Cancer Society have indicated that the five-year survival rate in multiple myeloma has significantly improved from 24% in 1975 to 28% in 1995 [11] . We believe that this improvement can be attributed to the RCTs and that these findings together demonstrate to the patient that RCTs may often represent the best available care. However, the quality of RCT reports in multiple myeloma is modest at best, clouding the scientific interpretation and immediate clinical usefulness of these studies
With the mounting empirical evidence that poor reporting quality is associated with bias, as well as obscuring the true methodological validity of the trial from the reader, initiatives like the CONSORT statement in 1996 have attempted to raise the standard of randomized controlled trial reporting [32] Recently, a revised CONSORT statement has re-enforced the importance of adequate reporting of RCTs and produced a document empirically demonstrating that poor reporting is associated with biased estimates of treatment effects [33, 34] Now manuscript submissions to many journals must submit a 22 point quality checklist as well as a flow chart describing patient enrollment, randomization and withdrawal However, most RCTs ultimately get published [3] , and it has been shown that many RCTs rejected from one journal end up published somewhere else unchanged [35] Although our analysis shows some degree of improvement in reporting on some quality dimensions, such as intention to treat analysis, these gains were relatively modest. Unfortunately, our observations on the low overall quality of myeloma trials are not unique to this setting, and have been made before in a variety of diseases [34, 36] . Our findings support the continuing mission of CONSORT that authors and editors alike must continually seek to better the quality of randomized trial reporting Although we stress the importance of enhancing the quality of the conduct and reporting of RCTs, we should not be disappointed with the modest results of innovative efforts in the management of multiple myeloma The survival gains observed here reflect the incremental nature of knowledge gain in medical science In addition, the informative nature of true negative results should also be understood as 'positive' since they help us to eliminate ineffective therapies [37] Certainly, many more inconclusive results could have been avoided if investigators adhered to good practice in clinical trial design. Improving the quality and conduct of RCTs would unquestionably accelerate the introduction of efficacious innovations into practice
The major limitation of this study was the lack of access to unpublished clinical trials. Establishment of a mandatory national clinical trial registry would greatly add to our ability to judge bias in the available body of evidence However, physicians, patients, and health policy makers have to base their decisions on available published literature Therefore, it is important to know the status of the quality of this evidence. Our analysis may provide them with an assessment of the quality of knowledge in this area Even if we were able to include unpublished data, our results would likely be even more disappointing since unpublished trails are usually negative and more biased [38] . Furthermore these results can only be applied to randomized controlled trials, which we found to represent only a minority of the existent clinical trial literature in myeloma. The rest of the literature contains small phase I and II toxicity studies that set the stage for randomized controlled trials but cannot usually be used to evaluate the relative efficacy of an innovative treatment The type of analysis presented here can provide us with an overview of the relative success of our research efforts and may indicate where future research and clinical trials should be directed. For example, our data suggest greater proportions of innovative successes occur among studies with non-survival outcomes as main endpoints in trials (Figure 2 ). However, if we desire to improve outcomes in future trials, sample size should be large enough to detect the minimal clinically important difference and not be based on an overly optimistic possible survival difference (Figure 3) . In addition these trials should incorporate adequate methodological standards shown to be lacking in trials performed so far (e.g., adequate allocation concealment, intention to treat analysis, etc)
